MUHAMMAD A KHAN, M



MUHAMMAD AKRAM KHAN, M.D., M.B.A., F.A.C.C., F.S.C.A.I.

4201 MEDICAL CENTER DRIVE, SUITE 380, MCKINNEY, TX 75069

Office: 972-529-6939 Fax: 972-529-6935

EDUCATION:

POSTGRADUATE TRAINING: 2011-2013 Physician Executive MBA

UT Southwestern Medical Center at UTD

Richardson, Texas

1996-97 Fellowship in Interventional Cardiology

Baylor University Medical Center

Dallas, Texas

96. Fellowship in Cardiology

Baylor University Medical Center

Dallas, Texas

93. Residency in Medicine

Wayne State University Medical Center

Detroit, Michigan

93. Internship in Medicine

Wayne State University Medical Center

Detroit, Michigan

MEDICAL SCHOOL: 1982-89 Dow Medical College

Karachi, Pakistan – M.B.B.S.

COLLEGE: 1979-81 St. Patrick’s College

Karachi, Pakistan

HOSPITAL/ACADEMIC

APPOINTMENTS:

July 2013 Laureate, American College of Cardiology

2003-Present Physician / President

Cardiac Center of Texas, P.A.

McKinney, Texas

February 2013 - Present Co-Director

Department of Palliative Care at Medical Center of Plano

2007-Present Co-Director

Department of Peripheral Vascular Disease at Medical Center of Plano

November 2010 – Present Medical Director

Preventive Medicine Department at Medical Center of Plano

July 2009 Founding Member IRB Committee at The Medical Center of Plano

2000-Present Principal Investigator

NORTH DALLAS RESEARCH ASSOCIATES

McKinney, Texas

2005, 2002, 2001, 2000, 1999 Chief of Cardiology Dept.

Medical Center of McKinney/North Central Medical Center

McKinney, Texas

2002-2004 Department Chair of Medicine

Presbyterian Hospital of Allen

Allen, Texas

2004 Peer Review Committee Member

North Central Medical Center Hospital

McKinney, Texas

2004 Vice-Chief of Cardiology

North Central Medical Center Hospital

McKinney, Texas

2002 Pharmacy & Therapeutics Committee Member

Medical Center of Plano

Plano, Texas

2002 Member

Cardiovascular Performance & Improvement Team

North Central Medical Center Hospital

McKinney, Texas

2002-2003 Physician / Vice President

Cardiovascular Physicians of North Texas, P.A.

McKinney, Texas

1997-2002 Director of McKinney Clinic

CPR / HeartPlace

McKinney, Texas

2003 Fellow, Society for Cardiac Angiography & Interventions

1999-2003 Director of Cardiac Catheterization Lab

North Central Medical Center

McKinney, Texas

1992-93 Chief Medical Resident

Wayne State University Medical Center

Detroit, Michigan

1999 Fellow, American College of Cardiology

BOARD CERTIFICATION(S):

2013 Diplomat in Phlebology

American Board of Venous and Lymphatic Medicine

2012 Diplomat in Hospice and Palliative Medicine

American Board of Internal Medicine

2000 Diplomat in Interventional Cardiology

American Board of Internal Medicine – Recertification 2012

1998 Diplomat in Cardiovascular Disease

American Board of Internal Medicine – Recertification 2009

1993 - 2008 Diplomat in Internal Medicine

American Board of Internal Medicine

OTHER CERTIFICATION:

2011 Certified Clinical Research Professional

Society of Clinical Research Associates

STATE LICENSURE(S):

Licensed Physician, State of Texas

MEMBERSHIPS:

American College of Phlebology

American Academy of Hospice and Palliative Medicine

Society of Clinical Research Associates

Society of Cardiovascular Computed Tomography – Level 2 Accredited

Society for Cardiovascular Angiography & Interventions

Wyeth Pharmaceuticals Visiting Speakers Bureau

Forest Pharmaceuticals Visiting Speakers Bureau

Medical Group Management Association

Academy of Physicians in Clinical Research

Association of Clinical Research Professionals

International Society of Endovascular Specialists

Outpatient Endovascular and Interventional Society

American College of Cardiology

American Heart Association

American College of Physicians

Texas Medical Association

Collin-Fannin County Medical Society

Society for Women’s Health Research

HONORS: First in Undergraduate School – Gold Medallist

Among top 1% on all professional exams

Federal Government Merit Scholarship

Pakistan Govt. Scholarship for Studying Medicine Abroad

PUBLICATIONS:

1. Khan, MA, Granda J. An atypical case of pituitary apoplexy. Abstract presented at 1991

Annual Session. ACP, Michigan Chapter

2. Spears, JR, Yellayi SS, Khan MA, Promm B. Effects of thermal exposure on binding of heparin in vivo to the arterial wall and to clot and on the chronic angiographic luminal responses to local application of a heparin film during angioplasty in an in view rabbit model. Lasers in Surgery Medicine. 1994;14:329-346.

3. Khan MA, Gerber TL, Anwar A. Percutaneous interventions for significant narrowings in saphenous vein aortocoronary conduits. Baylor University Medical Center Proceedings. 1995;5:19-25.

4. Khan MA, Gerber TX, Schreibfeder MM, Bret JR, Donsky MS, Leonard BM, Solis RM, Anwar A. The Elderly and Angioplasty: Does Gender Affect Outcome? American Journal Ger Cardiology. 1996;5(2):55.

ONGOING RESEARCH PROJECTS:

DAPT: A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Anti-platelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions.

CELESTIAL: Post Approval Registry: Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar Post Approval Registry.

GALAXY Registry: Long-term Evaluation of the Linox Family ICD Leads Registry.

PROMISE: PROspective Multicenter Imaging Study for Evaluation of Chest Pain

1160.128: A prospective, open label study evaluating the efficacy of two management strategies (pantoprazole 40 mg q.a.m. and taking Pradaxa with food (within 30 minutes after a meal) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa 150mg b.i.d for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation)

LIGHT STUDY: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR

CANTOS TRIAL: A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.

EUCLID: A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with 

established Peripheral Artery Disease

BIOFLEX-I: The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents.

BIOHELIX: The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent

BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

PRIOR RESEACH PROJECTS:

Sub-Investigator Micardis Community Access Trial (MICCAT)

Investigator Hyperlipidemia Study with Mayo Physician Alliance for Clinical Trials

Investigator Hypertension and Hyperlipidemia Study

Investigator Hypertension Study

Investigator Hyperlipidemia Study

A Randomized, Double-Blind, Placebo- Controlled, Multicenter, Parallel-Arm Study to Assess the Long-Term Effects of XXX Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease, 2003.

Effect of XXX Vs Placebo on a Background of Standard Care Including Aspirin, in Maintaining the Patency of Lower Limb Arteries After Angioplasty, 2003

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Forced Titration, Comparison of XXX (XXX 80mg/XXX 25mg) Versus YYY (YYY 160mg/ YYY25mg) using Seated Trough Cuff Blood Pressure in Patients with Stage 1 and Stage 2 Hypertension, 2003

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of XXX in the Treatment of Patients with Type 2 Diabetes Mellitus, 2003

A Placebo-Controlled Trial of XXX Added to Standard Therapy in African American Heart Failure, 2003

A Dose Response of XXX ER/YYY on Peak Walking Time (PWT) in Patients with Intermittent Claudication, 2003

An open-Label, Comparative Efficacy Evaluation of Lipids Levels when Treated with XXX and YYY or Other Lipid-Modifying Therapies, 2004

A Double-Blind, Randomized, Comparator-Controlled Study in Subjects with Type 2 Diabetes Mellitus Comparing the Effects of XXX HCL Versus YYY on the Rate of Progression of Coronary Atheroscelrotic Disease as Measured by Intravascular Ultrasound, 2004.

The Effect of XXX ER/YYY on Peak Walking Time in Patients with Intermittent Claudication, 2004

A phase 3 double blind randomized multisite trial of the efficacy, safety and tolerability of the fixed combination XXX/XXX administered orally, once daily for 12 months compared to XXX alone titrated based on NCEP ATP-III LDL-C goals in subjects with Fredrickson Types IIA and IIB Dyslipidemias, 2005

User Versus Tech Study Using the CoaguChek XS Meter with CoaguChek XS System PT Tests, 2005

A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of XXX400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (AF/AFL), 2005

A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of XXX 50 MG, 100 MG or Placebo When Co-Administered with XXX 10 MG or 20 MG in Subjects with Primary Hypercholesterolemia, 2005

An 8-Week, Randomized, Double-Blind, Parallel Group, Multi-Center, Placebo and Active Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of XXX (150 Mg and 300 Mg) Administered Alone and in Combination with XXX (160 Mg and 320 Mg) in Patients with Hypertension, 2006

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 4 x 4 Factorial Design to Evaluate XXX 20, 40 and 80 Mg Tablets in Combination with XXX 2.5, 5 and 10 Mg Capsules After Eight Weeks of Treatment in Patients with Stage I or II hypertension, With an ABPM Sub-Study, 2006

 A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of XXX and XXX Combination Therapy to XXX and XXX Monotherapy in Subjects with Mixed Dyslipidemia, 2006

A Long Term, Open-Label, Safety Extension Study of the Combination of XXX and XXX Therapy for Subjects with Mixed Dyslipidemia, 2006

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of XXX, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease, 2006

Randomized Evaluation of Long Term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of XXX with Open Label XXX for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial, 2006

Sub-Investigator Micardis Community Access Trial (MICCAT)

Investigator Hyperlipidemia Study with Mayo Physician Alliance for Clinical Trials

Investigator Hypertension and Hyperlipidemia Study

Investigator Hypertension Study

Investigator Hyperlipidemia Study

A Randomized, Double-Blind, Placebo- Controlled, Multicenter, Parallel-Arm Study to Assess the Long-Term Effects of XXX Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease, 2003.

Effect of XXX Vs Placebo on a Background of Standard Care Including Aspirin, in Maintaining the Patency of Lower Limb Arteries After Angioplasty, 2003

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Forced Titration, Comparison of XXX (XXX 80mg/XXX 25mg) Versus YYY (YYY 160mg/ YYY25mg) using Seated Trough Cuff Blood Pressure in Patients with Stage 1 and Stage 2 Hypertension, 2003

A Multi-center, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of XXX in the Treatment of Patients with Type 2 Diabetes Mellitus, 2003

A Placebo-Controlled Trial of XXX Added to Standard Therapy in African American Heart Failure, 2003

A Dose Response of XXX ER/YYY on Peak Walking Time (PWT) in Patients with Intermittent Claudication, 2003

REFERENCES: Available upon request.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download